Epilepsy is categorized as a chronic disease of the brain and continues to affect millions of individuals worldwide. Although the prevalence of epilepsy is marginally higher in men compared to women, it affects individuals from all age groups. The prevalence of focal seizures is higher than that of generalized seizures in both, children as well as adults. The prevalence of epileptic seizures is higher in low to middle-income countries due to which, the demand for epileptic seizure treatment is high from developing regions. Some of the major factors responsible for the high prevalence of epileptic seizures in developing regions include acute symptomatic seizures, misdiagnosis, and lack of advanced medical infrastructure.
πππ πππ¦π©π₯π πππ©π¨π«π πππ : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=79717
As epilepsy continues to emerge as a critical cause of mortality and disability around the world, considerable attention has been given to the development and discovery of new epileptic seizures treatmentβ a factor that is expected to drive the epileptic seizures treatment market during the forecast period. At present, players involved in the current epileptic seizures treatment market are increasingly focusing on reducing the burden of epileptic seizures, improving the access to the existing epileptic seizures treatments, and development of new vaccines and drugs particularly in the low/middle-income countries.
- Key players analyzed in the epileptic seizures treatment market report are
- Bausch Health Companies, Inc.
- GlaxoSmithKline plc.
- UCB S.A.
- Pfizer, Inc.
- Apotex, Inc.
- Alexza Pharmaceuticals, Inc.
- Neurelis, Inc.
- Veriton Pharma